Alpine Immune Sciences competitors

Alpine Immune Sciences Competitors include X4 Pharmaceuticals, G1 Therapeutics, PDL BioPharma and Rexahn Pharmaceuticals.
Add company...
Alpine Immune Sciences
Modern therapies targeting the immune synapse.
X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
G1 Therapeutics
G1 is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer.
PDL BioPharma
PDL BioPharma, Inc. engages in intellectual property asset management, and patent portfolio and related assets investment activities.
Rexahn Pharmaceuticals
Rexahn Pharmaceuticals develops treatments for cancer, central nervous system disorders, and other unmet medical needs in the United States.
Founding Date
Founding Date
2015
Founding Date
2012
Founding Date
2008
Founding Date
1986
Founding Date
2001
Type
Type
Private
Type
Private
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Seattle, US HQ
Locations
Cambridge, US HQ
Locations
Durham, US HQ
Locations
Incline Village, US HQ
Locations
Rockville, US HQ
Employees
Employees
N/A
Employees
303% increase
Employees
3827% increase
Employees
11
Employees
20
Valuation ($)
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
1.6 b
Valuation ($)
372.2 m
Valuation ($)
36.8 m

Financial

Revenue (est.)
Revenue (est.)
$1.7m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
$320.1m (FY, 2017)
Revenue (est.)
N/A
Net income
Net income
($7.8m) (FY, 2017)
Net income
N/A
Net income
($60.1m) (FY, 2017)
Net income
N/A
Net income
($25.3m) (FY, 2017)

Funding

Latest funding round
Latest funding round
$ 48m (over 2 years ago)
Latest funding round
$ 27m (11 months ago)
Latest funding round
N/A
Latest funding round
N/A
Latest funding round
N/A
Total funding raised
Total funding raised
$ 49.3m
Total funding raised
$ 64.5m
Total funding raised
$ 92.5m
Total funding raised
N/A
Total funding raised
$ 5m
For sources of this data, please see the company profileDownload Excel

View company profiles

X4 Pharmaceuticals
HQ
Cambridge, US
Employees
30↑ 3% increase

X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.

View company
G1 Therapeutics
HQ
Durham, US
Employees
38↑ 27% increase

G1 is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer.

View company
PDL BioPharma
HQ
Incline Village, US
Employees
11

PDL BioPharma, Inc. engages in intellectual property asset management, and patent portfolio and related assets investment activities.

View company
Rexahn Pharmaceuticals
HQ
Rockville, US
Employees
20

Rexahn Pharmaceuticals develops treatments for cancer, central nervous system disorders, and other unmet medical needs in the United States.

View company